Blood thinner safety study comparing two enoxaparin brands
Treatments studied
This early-stage study compares how your body responds to an enoxaparin biosimilar (a new version of a blood thinner) versus the original brand Clexane. Researchers want to confirm the new version works the same way and is safe in healthy adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a healthy adult aged 21–55 years old
- Have a normal weight (BMI 18.5–30, at least 45 kg)
- Have normal blood pressure, heart rate, and body temperature at screening
- Not be allergic to enoxaparin or have any bleeding disorder
- Not take any other medications, herbal products, or over-the-counter drugs for 2 weeks before the study
- Be willing to fast, avoid alcohol and caffeine, and not smoke for specific time periods during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares giving enoxaparin (a blood thinner) in two different spots on the body (belly vs. thigh) for patients with severe obesity who need to prevent blood clots after surgery or hospital stay. The goal is to see which injection site works best.
This trial tests if a higher dose of a blood thinner (enoxaparin) works better than the standard dose to prevent dangerous blood clots in the legs or lungs after a severe injury. It is for adults in the intensive care unit who are expected to stay more than 48 hours.
This trial compares three different blood thinners (heparin, argatroban, and enoxaparin) used during ECMO support. It aims to find the safest and most effective way to prevent blood clots while on ECMO.
This trial tests how the blood thinner edoxaban works in people with nephrotic syndrome, a kidney condition that raises clot risk. It compares results with healthy volunteers to see if the drug is safe and effective for you.
This is an early-stage safety study testing a new experimental medicine that affects blood clotting in people with no serious health conditions. Researchers want to make sure the medicine is safe and well-tolerated before testing it in patients who need it.
This trial tests how a blood thinner called enoxaparin works in intensive care patients with kidney problems, including those on a kidney replacement therapy (CVVH). The goal is to see if the drug prevents clots safely in these patients.
Hear when a new Healthy Participants Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.